Mark J. McKeage

6.8k total citations
143 papers, 5.5k citations indexed

About

Mark J. McKeage is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Mark J. McKeage has authored 143 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 54 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Mark J. McKeage's work include Lung Cancer Treatments and Mutations (43 papers), Cancer Treatment and Pharmacology (39 papers) and Metal complexes synthesis and properties (29 papers). Mark J. McKeage is often cited by papers focused on Lung Cancer Treatments and Mutations (43 papers), Cancer Treatment and Pharmacology (39 papers) and Metal complexes synthesis and properties (29 papers). Mark J. McKeage collaborates with scholars based in New Zealand, Australia and United States. Mark J. McKeage's co-authors include Bruce C. Baguley, Jianzhong Liu, Susan J. Berners‐Price, D Screnci, Peter Galettis, Lenushka Maharaj, Michael B. Jameson, Stephen M. F. Jamieson, Nancy N. Jong and R.J. Bowen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Mark J. McKeage

142 papers receiving 5.4k citations

Peers

Countries citing papers authored by Mark J. McKeage

Since Specialization

Citations

This map shows the geographic impact of Mark J. McKeage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. McKeage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. McKeage more than expected).

Fields of papers citing papers by Mark J. McKeage

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. McKeage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. McKeage. The network helps show where Mark J. McKeage may publish in the future.

Co-authorship network of co-authors of Mark J. McKeage

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. McKeage. A scholar is included among the top collaborators of Mark J. McKeage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. McKeage. Mark J. McKeage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy 2024 ·JMIR Research Protocols ·(unknown), Joanne Barnes, George Laking, (unknown), (unknown), (unknown), S. Delany, (unknown), (unknown), (unknown), (unknown), Ross Lawrenson, (unknown), Sandar Tin Tin, Mark Elwood, (unknown), Mark J. McKeage	0
2	Risk of cardiovascular disease in cancer survivors: A cohort study of 446,384 New Zealand primary care patients 2023 ·Cancer Medicine ·(unknown), Romana Pylypchuk, Mark Elwood, Mark J. McKeage, Sue Wells, Vanessa Selak	3
3	Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in Māori and Pacifica in New Zealand 2021 ·PLoS ONE ·(unknown), Mark J. McKeage, Sandar Tin Tin, (unknown), Mark Elwood	7
4	Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand 2020 ·BMC Cancer ·(unknown), Sandar Tin Tin, Mark J. McKeage, (unknown), Alana Cavadino, Mark Elwood	9
5	Factors associated with overall survival in a population-based cohort of non- squamous NSCLC patients from northern New Zealand: A comparative analysis by EGFR mutation status 2020 ·Cancer Epidemiology ·(unknown), Mark J. McKeage, Sandar Tin Tin, (unknown), Mark Elwood	3
6	Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non‐small‐cell lung cancer in New Zealand 2019 ·Internal Medicine Journal ·Mark J. McKeage, Sandar Tin Tin, (unknown), (unknown), Amanda Dixon‐McIver, Daniel Ng, Richard Sullivan, (unknown), P Shepherd, George Laking, (unknown), (unknown), Christopher Lewis, Mark Elwood, Donald R. Love	12
7	Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand 2018 ·Cancer Epidemiology ·Sandar Tin Tin, Mark J. McKeage, (unknown), (unknown), Mark Elwood	9
8	Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation 2017 ·Scientific Reports ·Catherine Han, (unknown), Andrew Hill, Gordon M. Miskelly, Mark J. McKeage	13
9	Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent 2014 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), Wayne R. Joseph, Graeme J. Finlay, James W. Paxton, Mark J. McKeage, Bruce C. Baguley	9
10	Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons 2012 ·Biochemical Pharmacology ·Jianzhong Liu, (unknown), Yan Fang, (unknown), (unknown), Nancy N. Jong, Julian F. B. Mercer, Mark J. McKeage	33
11	Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability 2010 ·BMC Cancer ·Andrew Hill, Peter S. Bergin, (unknown), Paul Thompson, Michael Findlay, Dragan Damianovich, Mark J. McKeage	42
12	Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer 2009 ·Lung Cancer ·Mark J. McKeage, Martin Reck, Michael B. Jameson, Mark Rosenthal, David D. Gibbs, Paul N. Mainwaring, Lutz Freitag, Richard Sullivan, Joachim von Pawel	77
13	COMPARATIVE PROTEIN BINDING, STABILITY AND DEGRADATION OF SATRAPLATIN, JM118 AND CISPLATIN IN HUMAN PLASMA IN VITRO 2008 ·Clinical and Experimental Pharmacology and Physiology ·(unknown), Jianzhong Liu, Malcolm D. Tingle, Benno Rattel, (unknown), Mark J. McKeage	20
14	P3-116: Phase II study of DMXAA (AS1404) 1800 mg/m2 combined with carboplatin and paclitaxel in non-small cell lung cancer 2007 ·Journal of Thoracic Oncology ·Mark J. McKeage, Joachim von Pawel	3
15	Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective. 2006 ·PubMed ·Rita Sasidharan, David D. Gibbs, Richard Sullivan, Andrew Simpson, David Díaz-Pérez, Timothy Christmas, Mark J. McKeage	1
16	Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss 2005 ·Cancer Chemotherapy and Pharmacology ·Stephen M. F. Jamieson, Jianzhong Liu, Bronwen Connor, Mark J. McKeage	97
17	Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes 2000 ·Cancer Chemotherapy and Pharmacology ·Mark J. McKeage, Susan J. Berners‐Price, Peter Galettis, R.J. Bowen, W G Brouwer, Li Ding, Li Zhuang, Bruce C. Baguley	185
18	Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches 1999 ·Journal of Inorganic Biochemistry ·D Screnci, Mark J. McKeage	121
19	Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. 1994 ·PubMed ·Mark J. McKeage, (unknown), Michael Jones, K.R. Harrap	36
20	Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents 1993 ·British Journal of Cancer ·Mark J. McKeage, (unknown), (unknown), (unknown), (unknown), KR Harrap	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact